BMC Pulmonary Medicine (Jan 2019)

Characterizing idiopathic pulmonary fibrosis patients using US Medicare-advantage health plan claims data

  • Kathleen Mortimer,
  • Nadine Hartmann,
  • Christine Chan,
  • Heather Norman,
  • Laura Wallace,
  • Cheryl Enger

DOI
https://doi.org/10.1186/s12890-018-0759-5
Journal volume & issue
Vol. 19, no. 1
pp. 1 – 13

Abstract

Read online

Abstract Background Idiopathic pulmonary fibrosis (IPF) is a rare life-threating interstitial lung disease (ILD). This study characterizes demographics, health care utilization, and comorbidities among elderly IPF patients and estimates prevalence and incidence rates for selected outcomes. Methods Cohort study using a large US health insurance database (Optum’s Medicare Advantage plan). Inclusion criteria: ≥ 1 diagnosis code for IPF (2008 - 2014), age ≥65 years, no diagnosis of IPF or other ILD in prior 12 months. Demographics, health care utilization, comorbidities and incidence rates for various outcomes were estimated. Follow-up continued until the earliest of: health plan disenrollment, death, a claim for another known cause of ILD, or end of the study period. Results 4,716 patients were eligible; 53.4% had IPF diagnostic testing. Median age was 77.5 years, 50.3% were male, median follow-up time was 0.8 years. Incidence rates ranged from 1.0/1,000 person-years (lung transplantation) to 374.3/1,000 person-years (arterial hypertension). Baseline characteristics and incidence rates were similar for cohorts of patients with and without IPF diagnostic testing. Conclusions Elderly IPF patients experience a variety of comorbidities before and after IPF diagnosis. Therapies for IPF and for the associated comorbidities may reduce morbidity and associated health care utilization of these patients.

Keywords